Biotech IT & AI consultingScience, and the speed to believable evidence.

Biotech lives or dies on the science and on how fast the company can turn it into evidence investors and regulators will believe.

Primary shape of the AI dividend this year: Rising Bar.

A technology estate nobody planned.

Between the science and the evidence sits a technology estate most emerging companies never planned: an ELN here, instrument software there, results in shared drives and spreadsheets.

We bring fractional CIO leadership into life-science companies through Contract CIO+®, ongoing technology counsel through CIO IQ®, and guidance for scientific AI.

Biotech in 2026.

Recovery meeting reinvention.

Capital

On discriminating terms

Capital is returning, with more discriminating expectations of the data behind each program.

Evidence

Investor-ready data

Results in shared drives and spreadsheets turned into evidence regulators and investors trust.

Estate

ELN and instruments

An integrated lab and data estate instead of scattered tools.

AI

From slideware to bench

AI is moving into the lab and needs governed data to work.

Shape

Rising Bar

Primary shape of the AI dividend this year.

Our top-line approach.

Technology that keeps pace with the science.

Stabilize

Secure and organize data across instruments, notebooks, and drives.

Optimize

Integrate the lab stack so evidence flows faster.

Monetize

Put AI to work at the bench to speed discovery.

Led by consultants from your industry.

Talk with a life-science technology leader.

A former CIO, CTO, or CISO from the sector, vendor-neutral, with the only agenda yours.